Advertisement: Kao Data Centre mid banner
Advertisement: Mogrify mid banner
Advertisement: Excalibur Healthcare mid banner
Barr Ellison Solicitors – commercial property
Advertisement: Simpsons Creative
Mid banner advertisement: BDO
Advertisement: Cambridge Network mid banner
Advertisement: partnersand mid banner
Advertisement: RSM mid banner
Advertisement mid banner S-Tech 1
Advertisement: HCR Hewitsons recruitment mid banner
Advertisement: CJBS mid banner
ARM Innovation Hub
Advertisement: EBCam mid banner
27 October, 2021 - 00:36 By Tony Quested

Cambridge Cognition secures £600k for schizophrenia trial with existing client

AIM-listed Cambridge Cognition, which develops and markets digital solutions to assess brain health, has secured a contract for a further sizeable schizophrenia trial with an undisclosed existing customer.

Cambridge Cognition has been selected to provide its proprietary digital cognitive assessments (CANTABTM), and specialist study management services to the client as part of a  contract worth more than £600,000 over three years.

Patients with schizophrenia often experience cognitive impairment, with deficits observed in memory, attention and executive function. Cmbridge Cognition says that CANTABTM cognitive assessments can measure these distinct processes with a high degree of sensitivity and so offers a valuable efficacy endpoint for the novel pharmaceutical being investigated.

Cambridge Cognition CEO,, Matthew Stork, said: "We are delighted with the enduring partnership we have formed with this client and the award of a further order for digital technology solutions from them. 

“This is also great news for us as our strategy is to broaden our offering and expand into more therapeutic areas. Demonstrating the value of digital cognitive assessments in schizophrenia drug development could provide for many more similar opportunities in the future."

Cambridge Cognition says its neuroscience technology solutions can detect early signs of cognitive impairment for appropriate intervention, and are a major component in the research and understanding of brain health.

Originally developed at the University of Cambridge, the Cambridge Neuropsychological Test Automated Battery (CANTAB) includes highly sensitive, precise and objective measures of cognitive function, correlated to neural networks.

The company says its CANTAB tests have demonstrated sensitivity to detecting changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control.

Newsletter Subscription

Stay informed of the latest news and features